JAN 03, 2020 3:19 PM PST

Researchers Grow Psilocybin from E. Coli Bacteria

WRITTEN BY: Annie Lennon

Previously considered to be narcotic, and under tight regulation as an illicit drug for decades, research from recent years on the possible medicinal properties of ‘magic mushrooms’ has blasted the fungus into mainstream healthcare discussions. With its new-found potential to treat mental health issues including depression, post-traumatic stress disorder and addiction, it may now be possible to grow its active psychedelic ingredient, psilocybin, in E. coli bacteria. 

J. Andrew Jones, researcher at Miami University and co-author of the study behind this process, said, “In theory, enough mushrooms could be grown, but it is not all that practical...Our production process, from beginning to end, only takes a few days to complete compared to much longer for mushrooms.”

For their study, Jones and his team engineered E. coli bacteria to contain three genes from the Psilocybe cubensis mushroom to enable the bacteria to synthesize psilocybin from the cheap and widely available precursor molecule 4-hydroxyindole. They then optimized the process to produce the compound on a larger scale, ultimately generating around 1.16g of psilocybin per liter per fermentation batch. 

Lead author of the study, undergraduate chemical engineering student Alexandra Adams, said, “The number-one advantage is it's simply cheaper” than—or at least cost-competitive with—other methods.” She added, “...it's easier to manipulate E. coli than other organisms.”

Dirk Hoffmeister, a pharmaceutical microbiologist at Friedrich Schiller University in Germany said that the study is “an intriguing alternative and proof of principle”. He did however warn that such engineered bacteria could produce toxic and allergenic microbial material that should be filtered out by purification. 

Currently, psilocybin is produced either by growing mushrooms containing the compound or by synthetic means in a multi-step process. As this method is both cheaper and faster than existing ways of producing psilocybin, the researchers suggest that it may pave the way towards its mass study and later production of safe psilocybin therapies. 

In particular, senior study author, Andrew Jones, aims to eventually adapt this process to be able to synthesize psilocybin from glucose. In the meantime, he and his colleagues are currently in discussions with several pharmaceutical companies about licensing their method for commercial usage. 


 

Sources: Inverse, Scientific American and Phys.org

 

About the Author
  • Annie graduated from University College London and began traveling the world. She is currently a writer with keen interests in genetics, psychology and neuroscience; her current focus on the interplay between these fields to understand how to create meaningful interactions and environments.
You May Also Like
NOV 28, 2019
Drug Discovery & Development
NOV 28, 2019
Immunotherapy Drug Shows Promise for Treating Advanced Prostate Cancer
By the end of the year, an estimated 175,000 men in the United States will have been diagnosed with prostate cancer. Now, researchers from the UK have foun...
DEC 12, 2019
Drug Discovery & Development
DEC 12, 2019
Probiotics Treat Alcohol-Induced Liver Injury
Alcoholic liver injury is caused by overconsumption of alcohol, something that can lead to serious diseases such as liver steatosis, liver cirrhosis and li...
DEC 25, 2019
Drug Discovery & Development
DEC 25, 2019
New Drug to Make Breast Cancer Treatment More Affordable
The US Food and Drug Administration has granted accelerated approval to new breast cancer drug, trastuzumab deruxtecan. The drug’s increasing recogni...
JAN 13, 2020
Drug Discovery & Development
JAN 13, 2020
Vaccine Against Alzheimer's to Hit Clinical Trials
Currently Alzheimer’s disease is thought to affect around 50 million people around the world, with this figure doubling every year. Currently with no...
JAN 18, 2020
Drug Discovery & Development
JAN 18, 2020
Drug Combo Targets Osteoarthritis
Individuals suffering from osteoarthritis often face challenges of limited treatment options mainly pain relievers or joint replacement surgery. However, s...
FEB 06, 2020
Drug Discovery & Development
FEB 06, 2020
China Begins Trials for Antiviral Drug to Tackle Coronavirus
So far, coronavirus has infected over 31,493 people globally, and has killed 638. Although 1,563 people have reportedly recovered, due to its fast-spreadin...
Loading Comments...